Lexaria Bioscience Corp. (NASDAQ: LEXX) announced the extension of a Material Transfer Agreement (MTA) originally signed on August 30, 2024, with a pharmaceutical company referred to as PharmaCO. The agreement has been extended through December 31, 2026, to allow time for PharmaCO to receive and review Lexaria's 2026 research and development results related to GLP-1 drugs. The extension maintains the temporary exclusive license and enables continued strategic planning discussions with PharmaCO's human clinical and business development teams.
The MTA was established to evaluate Lexaria's DehydraTECH technology in a pre-clinical setting. DehydraTECH is Lexaria's patented drug delivery formulation platform designed to improve oral drug absorption, reduce side effects, and enhance delivery across the blood-brain barrier. The technology has garnered a robust intellectual property portfolio with 65 granted patents and additional patents pending worldwide.
Over the past 12 months, Lexaria has advanced its GLP-1 development program, with progress reported in three 2026 R&D studies: Human Study #7, Animal Study #1, and Animal Study #2. All studies are within the GLP-1 sector and are designed to provide comprehensive evidence to facilitate further collaboration and potential licensing of Lexaria's technology. These studies are fully funded with existing corporate resources, and results are expected during the third and fourth quarters of 2026.
The extension of the MTA underscores the potential of Lexaria's DehydraTECH platform in the rapidly growing GLP-1 market, which includes drugs for diabetes and obesity. By enabling oral delivery of these often injectable medications, DehydraTECH could significantly improve patient compliance and convenience. The collaboration with PharmaCO, a pharmaceutical company, suggests that larger industry players are interested in leveraging Lexaria's technology to enhance their own drug pipelines.
Lexaria operates a licensed in-house research laboratory and continues to innovate in oral drug delivery. The company's focus on GLP-1 agonists aligns with a multi-billion-dollar market where oral formulations are highly sought after. The outcomes of the ongoing studies could have substantial implications for Lexaria's valuation and partnership opportunities.
For more information about Lexaria and its DehydraTECH technology, visit www.lexariabioscience.com.
